# Using Radiofrequency Ablation (Heat) to Treat Lung Tumors: What Patients Should Know About Success Rates, Safety, and What Predicts a Good Outcome Radiofrequency ablation (RFA) is a minimally invasive treatment that uses heat from radio waves to destroy tumors in the lung. In this study of 79 patients with 129 lung tumors that could not be treated with surgery, radiation, or chemotherapy, doctors achieved local tumor control in 85.3% of treated tumors. The strongest predictor of success was tumor size: tumors smaller than 2 cm responded far better than larger ones. Overall, the treatment proved safe, with a low rate of serious complications, making it an important option for people with limited lung cancer or tumors that have spread to the lungs. # Using Radiofrequency Ablation (Heat) to Treat Lung Tumors: What Patients Should Know About Success Rates, Safety, and What Predicts a Good Outcome ## Table of Contents - Key Points - Why This Research Matters: The Growing Need for Non-Surgical Lung Tumor Treatment - Study Overview: Who Participated and What Was Treated - The Procedure: How Radiofrequency Ablation Works - Key Finding #1: Most Tumors Were Successfully Controlled - Key Finding #2: Tumor Size Strongly Predicts Treatment Success - Key Finding #3: Distance to Blood Vessels, Airways, and the Lung Lining Did NOT Change Outcomes - Overall Survival: How Long Patients Lived After Treatment - Special Focus: Patients With Colorectal Cancer That Spread to the Lungs - Safety and Side Effects: What Patients Can Expect - How Does RFA Compare to Other Treatments? - Study Limitations: What This Research Could Not Prove - What This Means for Patients: Clinical Implications - Frequently Asked Questions - Source Information ## Key Points - In a study of 79 patients with 129 lung tumors, RFA controlled 85.3% of treated tumors during follow-up. - Tumor size strongly predicted success: tumors under 1 cm had only 7.3% regrowth, while 2–3 cm tumors had 28.6%. - The most common side effect was pneumothorax (14.7% of sessions); serious complications occurred in under 4% of procedures. - Distance of tumors to blood vessels, airways, or the lung lining did not significantly affect recurrence rates. - Patients whose treated tumor stayed controlled lived longer; median overall survival after RFA was 27 months. ## Why This Research Matters: The Growing Need for Non-Surgical Lung Tumor Treatment Surgery has long been the gold standard for early-stage non-small cell lung cancer (NSCLC), with 5-year survival rates ranging from 40% to 67% for stage I disease and 25% to 55% for stage II disease. Surgery is also the preferred treatment when cancer from another part of the body has spread (metastasized) to the lungs. However, not everyone can have surgery. Some patients have medical conditions that make anesthesia and operations too risky. Others have too many tumors, tumors in difficult locations, or advanced disease that means surgery would not help enough. For these patients, newer minimally invasive techniques have emerged as promising alternatives. Over the past decade, doctors have increasingly used image-guided therapies such as **percutaneous radiofrequency ablation (RFA)**, which delivers heat energy directly into a tumor through a needle placed through the skin (percutaneous means "through the skin"). The images guiding the needle come from CT scans (computed tomography, a detailed 3D X-ray). The purpose of this study, conducted at a German university clinic, was to evaluate three things about RFA for both primary lung cancer (cancer that started in the lung) and secondary lung tumors (metastases that spread to the lung from elsewhere). The researchers wanted to know: - **Efficacy:** How well does RFA control tumor growth? - **Safety:** How common and how serious are the side effects? - **Predictive factors:** Which patient or tumor characteristics predict a better or worse outcome? The study was published in Oncotarget in January 2018. It was a retrospective (looking back at past cases), single-center study. This means researchers reviewed the records of patients treated at one university hospital over a 6-year period. ## Study Overview: Who Participated and What Was Treated The study included **79 patients** treated over a 6-year period at the Otto-von-Guericke University Clinic in Magdeburg, Germany. The group included 47 men (60%) and 32 women (40%), with a median age of 65.1 years (the middle age of the group; the full range was 36 to 83 years). These 79 patients had a total of **129 lung tumors** (some patients had multiple tumors). All patients were considered unsuitable for surgery, radiation therapy, or chemotherapy — the three more traditional treatment options. Treatment decisions were made by a multidisciplinary team that included an interventional radiologist, an oncologist, a surgeon, and a pathologist. The types of tumors treated were diverse: - 74 pulmonary metastases from **colorectal cancer** (cancer of the colon or rectum) - 13 lesions from **malignant melanoma** (a serious form of skin cancer) - 13 metastases from **renal (kidney) cancer** - **5 primary lung malignancies** (lung cancer that started in the lung itself) - **24 tumors of other cancer types** Eligibility for the procedure required meeting several inclusion criteria. Patients needed: 1. Pulmonary (lung) lesions that were inoperable — surgery was not an option 1. Poor candidacy for surgery due to medical conditions, or unsuitable candidacy due to advanced cancer-related health problems 1. Unsuitability for radiotherapy or chemotherapy 1. Lesions with a maximum diameter smaller than 4 cm (about 1.6 inches) 1. A diagnosis where lung tumors had not infiltrated (invaded) the chest wall or mediastinal structures (the area between the lungs containing the heart and major blood vessels) 1. An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 — a standard scale measuring how well a patient can carry out daily activities — and a platelet count (blood clotting cells) greater than 100 × 10⁹/L Patients were excluded from the study under these conditions: 1. They were considered high-risk for RFA due to major co-existing medical conditions 1. They had more than three lesions per lung 1. Their ECOG performance status was above 2 (meaning significant disability) 1. Their platelet count was equal to or less than 100 × 10⁹/L Importantly, a history of prior chest surgery was *not* a reason to exclude a patient. Eighteen patients (22.5%) had undergone thoracic (chest) surgery in the past. This detail matters because prior surgery can cause scar tissue that makes later procedures more complicated. All patients gave written informed consent, and the hospital's institutional review board (IRB) — an ethics committee that approves research studies — gave approval for the retrospective design. ## The Procedure: How Radiofrequency Ablation Works Understanding the procedure helps patients know what to expect. RFA uses an electrical generator (the RF3000®, made by Boston Scientific, USA) that delivers up to 200 watts of power through expandable needle electrodes (the LeVeen® needle). The procedure destroys tumor cells by heating them to temperatures that cause cell death — essentially "cooking" the tumor. All procedures were performed using CT guidance (either a 16-row or 64-row CT scanner, both made by Toshiba). Before the procedure, patients received intravenous (into-the-vein) sedation with Midazolam (a sedative) and Fentanyl (a painkiller), given on demand, plus local anesthesia with Xylocaine to numb the skin and deeper tissues. The steps of the procedure can be broken down as follows: 1. **Positioning:** The doctor positioned each patient based on the most optimal skin entry site shown on the CT scan. 1. **Needle Insertion:** The needle electrode was inserted through the skin under sterile conditions, following the shortest, safest path to the tumor while avoiding critical structures such as the pleura (thin lining around the lungs), blood vessels, and bronchial tubes (airways). 1. **Ablation:** Once the needle was confirmed to be correctly placed inside the tumor, the radiofrequency energy was delivered in step-wise settings. The ablation algorithm varied based on tumor location and its distance from the pleura. 1. **Second Cycle:** After the first ablation cycle automatically stopped (called "roll-off" in impedance-control mode, meaning tissue resistance rose as tissue cooked), a second cycle was performed at 70% of the original maximum power. 1. **Safety Margin:** The ablation area always included a 0.5 cm (about 0.2 inch) safety margin of normal-looking tissue around the tumor. This margin is standard practice to catch microscopic cancer cells that may have spread just beyond the visible tumor edge. 1. **Track Ablation:** While pulling the needle out, the doctor applied 10 watts of energy along the needle track. This "track ablation" destroys any cancer cells that might have stuck to the needle, and it helps prevent bleeding into the chest cavity. 1. **Final Scan and Monitoring:** After finishing, the doctor performed a CT scan of the ablation area to confirm technical success and check for early complications. Patients were then kept under observation while staff monitored their heart, lungs, and overall condition. 1. **Chest X-rays:** To monitor for delayed collapse of the lung (pneumothorax), X-rays were taken at 4 hours and 24 hours after each procedure in all patients. Technical success was defined as correct needle placement with completion of the full standard ablation protocol. An important practical detail for patients: the median procedure time was only **17 minutes** (range: 10 to 30 minutes). ## Key Finding #1: Most Tumors Were Successfully Controlled Patients were followed with CT scans for a median of **14 months** after treatment (with individual follow-ups ranging from 3 to 81 months, or nearly 7 years). The primary measure of success was **local tumor control (LTC)** — the percentage of treated tumors that did not grow back at the treatment site. This is a strong result: **LTC was achieved in 110 of 129 treated tumors, or 85.3%.** In other words, about 85 out of every 100 treated tumors stayed controlled during the follow-up period. To classify tumor responses, the researchers used a standard international set of criteria called **RECIST 1.1** (Response Evaluation Criteria in Solid Tumors), which measures changes in tumor size on imaging scans. The specific response categories were: - **Complete remission (CR):** 34 lesions (26.4%) — the tumor completely disappeared on the follow-up CT scan. - **Partial remission (PR):** 48 lesions (37.2%) — the tumor shrank by at least 30% in its longest diameter. - **Stable disease (SD):** 28 lesions (21.7%) — the tumor neither shrank enough to qualify as remission nor grew enough to qualify as progression. - **Progressive disease (PD):** 19 lesions (14.7%) — the tumor grew at the treatment site, indicating incomplete ablation or recurrence. To summarize in plain terms: about 26% of treated tumors vanished completely, another 37% shrank substantially, and roughly 22% stayed the same size. Only about 15% continued to grow despite treatment. Two experienced radiologists — with 7 and 13 years of experience in oncological/interventional radiology — independently reviewed all CT scans. When their readings disagreed, they discussed the case and reached a consensus. Scans were evaluated on three measures: the longest tumor diameter measured on axial (horizontal) views, the tumor geometry (shape), and whether the tumor showed contrast enhancement (uptake of contrast dye, which suggests living tumor tissue with a blood supply). A key strength of the follow-up method was how doctors avoided "false positives." RFA creates a zone of coagulation necrosis (dead tissue) that appears as a high-density area on CT scans, and this can look like a tumor. To avoid misreading this as tumor progression, the researchers compared every follow-up scan side-by-side with a baseline scan taken shortly after ablation, rather than comparing to the pre-treatment scan. ## Key Finding #2: Tumor Size Strongly Predicts Treatment Success The most important finding of this study — and its most useful message for patients — is that **the initial tumor size had a significant influence on local tumor control.** Among the 129 tumors, sizes ranged from 0.5 cm to 3.0 cm in longest diameter, with a median (middle value) of 1.2 cm and a mean (average) of 1.3 cm. The breakdown was: - 41 tumors measured 0.5 to 1 cm - 74 tumors measured 1 to 2 cm - 14 tumors measured 2 to 3 cm The local progression (tumor regrowth) rates by size were striking: - Tumors of **0.5 to 1 cm:** local progression in only **7.3%** of cases (about 1 in 14) - Tumors of **1 to 2 cm:** local progression in **16.2%** of cases (about 1 in 6) - Tumors of **2 to 3 cm:** local progression in **28.6%** of cases (about 1 in 3.5) These differences were statistically significant, confirmed by two complementary statistical tests: the log-rank test (p = 0.013) and the Breslow test (p = 0.029). For readers not used to statistics, a p-value below 0.05 means there is less than a 5% chance the result happened by random luck. Here, the p-value of 0.013 means there is only a 1.3% chance this size effect is due to chance. Cox regression analysis — a statistical method that accounts for multiple factors at once — also confirmed tumor size as a meaningful predictor of local failure (p = 0.012). In practical terms, the message is clear: **smaller tumors respond better to RFA.** A tumor under 1 cm has more than a 90% chance of being controlled, while a tumor between 2 and 3 cm fails treatment almost 3 times as often. Interestingly, however, initial tumor size did *not* significantly affect overall survival (p = 0.659). The median overall survival was 26.2 months for patients with tumors of 0.5 to 1 cm, 26.0 months for those with 1 to 2 cm tumors, and 16.3 months for the 2 to 3 cm group. Even though the 2 to 3 cm group lived noticeably less long on average, the difference did not reach statistical significance — likely because that group contained only 14 tumors, too few to prove the difference wasn't by chance. ## Key Finding #3: Distance to Blood Vessels, Airways, and the Lung Lining Did NOT Change Outcomes A common worry in thermal ablation (heat-based tumor destruction) is the so-called "heat sink effect." Large blood vessels near a tumor can carry heat away, like a radiator, leaving parts of the tumor undercooked and alive. For this reason, researchers carefully analyzed whether tumor location relative to blood vessels, airways (bronchi), and the pleura (lung lining) mattered for recurrence. Surprisingly, **none of these distance factors had a statistically significant effect on local recurrence:** - Distance to the pleura: p = 0.807 (no significant effect) - Distance to blood vessels: p = 0.812 (no significant effect) - Distance to bronchi (airways): p = 0.820 (no significant effect) Here are the detailed numbers from the study: **Distance to the pleura:** Ten tumors were directly adjacent to the pleura (within 0 to 0.5 cm), and 119 were more than 1 cm away. Of the 10 pleural-adjacent tumors, 2 (20%) showed local recurrence. Among the 119 tumors at distance, 17 (14.3%) recurred. The difference was not statistically significant. **Relationship to vessels:** Looking at each treated lesion's relationship to nearby pulmonary vessels, 14 tumors sat directly against a vessel (0 to 0.5 cm away), 82 were between 0.5 and 2 cm away, and 33 were more than 2 cm away. After treatment, local recurrence occurred in 2, 12, and 5 tumors in each of those groups, respectively. **Relationship to bronchi:** Eight tumors were directly adjacent to an airway (0 to 0.5 cm), 61 were 0.5 to 2 cm away, and 60 were more than 2 cm away. Recurrences were 2, 10, and 7 in those groups, respectively. The researchers also measured the actual *diameter* of nearby vessels and bronchi (not just distance), thinking larger structures might cause bigger "heat sink" effects. The median diameter of an adjacent vessel was 0.4 cm (mean 0.6 cm; range 0.1 to 3 cm), and the median diameter of an adjacent bronchus was 0.4 cm (mean 0.5 cm; range 0.2 to 2 cm). Neither vessel diameter nor bronchus diameter influenced recurrence rates. This finding runs contrary to some earlier research. For example, a study by Schneider and colleagues reported that tumors in central or hilar locations (near the center of the lung where large vessels enter) most frequently showed a "heat sink effect," with viable (living) tumor cells found next to peripheral vessels after ablation. This study did not find that effect. ## Overall Survival: How Long Patients Lived After Treatment The median overall survival (OS) — the time by which half of patients had died and half were still alive — was **27 months** after RFA treatment. Survival was closely tied to whether local recurrence occurred. Patients whose treated tumor stayed controlled lived significantly longer. In contrast, patients who experienced a local recurrence had a median survival of only **14.9 months** — a difference that was statistically significant (p = 0.020). This makes biological sense: a tumor regrowing at the treatment site means active cancer continues to spread and threaten health. Looking at survival by initial tumor size category: - 0.5 to 1 cm tumors: median OS = 26.2 months - 1 to 2 cm tumors: median OS = 26.0 months - 2 to 3 cm tumors: median OS = 16.3 months Notice that patients in the smallest two groups lived nearly identical lengths of time (about 26 months), while the 2 to 3 cm group had substantially shorter survival. As noted above, however, this difference did not reach statistical significance in this small patient sample. ## Special Focus: Patients With Colorectal Cancer That Spread to the Lungs Because colorectal cancer metastases (spread to the lung from colon or rectal cancer) made up the largest single group — 74 of the 129 tumors — the researchers performed a subgroup analysis just on these patients. This is highly relevant information, since colorectal cancer is among the most common cancers that spread to the lungs. For patients with colorectal lung metastases treated with RFA: - Median overall survival was **13 months** - Median time to recurrence (how long before a treated tumor began growing again) was **8 months** The researchers compared these results to the published literature. A study by de Baere and colleagues — the largest RFA series ever reported, with 1,037 lung metastases from many primary cancer types — found a much better median overall survival of 62 months. The researchers explain this gap by pointing out that the de Baere study used stricter patient selection criteria, which would have excluded sicker patients and produced more favorable results. Other key studies put RFA results in context: - Iida and colleagues reported a 5-year overall survival rate of 53.5% after RFA for lung metastases in a Japanese multicenter registry. - A meta-analysis by Gonzalez and colleagues found 5-year survival rates ranging from 27% to 68% after RFA of lung metastases. - Yamakado and colleagues achieved 83% local tumor control in 155 treated lung metastases from colorectal cancer in a Japanese multicenter study. - Simon and colleagues studied 153 patients and found that lesions smaller than 3 cm had a significant positive influence on survival compared with larger lesions — consistent with what this German study found. Importantly, these survival rates are within the range of results obtained after surgical resection of lung metastases, which remains the standard treatment. This suggests RFA can offer comparable outcomes for patients who cannot undergo surgery. ## Safety and Side Effects: What Patients Can Expect The study documented complications using the **CTCAE** (Common Terminology Criteria for Adverse Events), an internationally recognized scale that grades side effects from Grade I (mild) to Grade V (death). The two most common complications were: - **Pneumothorax** (collapsed lung — air leaking into the space between the lung and chest wall): occurred in 19 cases (14.7% of treatment sessions, or about 1 in 7). - **Pleural effusion** (fluid collecting around the lung): occurred in 2 patients (1.6%). These two problems are the expected risks of any procedure that passes a needle through the chest wall and into the lung. Most pneumothoraces after RFA are small and resolve on their own without any treatment. The severity breakdown was: - **Minor complications:** recorded after 18 procedures (14%). These were self-limiting and tolerable. - **Major complications:** 5 events (3.9%), requiring additional treatment: - One patient (0.8%) required a small-bore drainage catheter for pneumothorax — rated CTCAE Grade II (moderate) - Two patients (1.6%) required a larger chest tube placement — rated CTCAE Grade III (serious but treatable) - One patient (0.8%) suffered a painful skin burn at the site of the grounding pad (the adhesive electrode placed on the skin that completes the electrical circuit) — rated CTCAE Grade III. - One patient (0.8%) developed a pulmonary abscess (a pocket of infection in the lung) after the procedure, requiring systemic (whole-body) antibiotic therapy — rated CTCAE Grade II. Critically, **there were no Grade IV or Grade V complications** (life-threatening events or deaths) caused by the ablation in this study. No patient experienced worsening of their underlying pulmonary function as a consequence of the procedure. These safety figures compare favorably with other published data. Other research series have reported: - Periprocedural (around-the-time-of-procedure) mortality of less than 1% - Periprocedural morbidity (illness/complications) ranging from 15.5% to 55.6% - Major complication rates between 8% and 12% in earlier clinical trials The numbers in this study — 14% minor and about 4% major complications — sit comfortably within the better end of these ranges. The most common complications in other series are, as here, pneumothorax and pleural effusion. Rare but serious issues include infection or hemorrhage from cavity formation when the dead tumor liquefies (colliquation), or post-interventional pneumonia, reported in up to 30% of cases in some literature. Skin burns around grounding pads, as seen in one patient in this series, are a known risk of monopolar radiofrequency ablation. For comparison, a prospective multicenter trial from Japan published in 2016 analyzed complications using CTCAE grading in 33 patients undergoing RFA. Two patients developed pleural effusion. Pneumothorax occurred in 12 of 33 patients (36% — more than double the rate in this German study), and 2 of those patients (6.7%) required chest tube placement. One patient experienced transient hypoxia (low blood oxygen, with oxygen saturation below 88%). The Japanese researchers hypothesized that the higher pneumothorax rate might reflect the fact that many of their patients had never had chest surgery before — meaning no scar tissue to tether the lung in place. The authors of the current study emphasize that while most complications are minor, radiologists must be ready to handle the rare serious ones quickly. They also recommend temperature monitoring at grounding pads during the procedure to prevent skin burns. ## How Does RFA Compare to Other Treatments? Patients today have multiple options for lung tumors when surgery is not possible. It helps to see how RFA compares to its closest competitors. **Stereotactic body radiation therapy (SBRT)** — a highly precise form of radiation — has reported local tumor control rates of 97.6% in some studies. **CyberKnife** stereotactic radiosurgery (another precise radiation method) has shown 95% local control. At first glance, these numbers look better than the 85.3% local control rate in this study. However, direct comparison between studies is difficult because patient populations differ in tumor sizes, cancer types, and overall health. A very informative study by Nour-Eldin and colleagues directly compared three heat-based ablation methods in the treatment of non-colorectal lung metastases: - **Laser-induced interstitial thermotherapy (LITT)** — using laser light to heat the tumor: 70.6% local tumor control - **Radiofrequency ablation (RFA)** — using radio waves: 79.3% local tumor control - **Microwave ablation (MWA)** — using microwave energy: 90.5% local tumor control Pneumothorax rates in that comparison study were 22.73% for LITT, 14.23% for RFA, and 22.16% for MWA. Notably, the RFA pneumothorax rate in the Nour-Eldin study (14.23%) almost exactly matched the rate in this German study (14.7%). These comparative numbers suggest that microwave ablation may control tumors somewhat better than RFA, and that RFA may cause fewer lung collapses than the other two heat methods. However, each technology has its own strengths, and the choice depends on tumor location, size, and what equipment the treatment center has available. The authors of this study conclude that RFA "still has its impact as an ablative oncologic therapy method," and they note the growing role of newer technologies such as microwave ablation and high-dose-rate (HDR) brachytherapy (a form of internal radiation therapy). ## Study Limitations: What This Research Could Not Prove Every good research paper acknowledges its own weaknesses, and this one is no exception. Understanding the limitations helps patients interpret the results correctly. **First, the retrospective design.** The researchers looked back at records of patients who had already been treated. Unlike a prospective randomized trial (where patients are randomly assigned to different treatments and followed forward in time), a retrospective study cannot prove cause and effect. It can only show associations. **Second, the patient group was heterogeneous.** The study included both primary lung cancer and many different types of metastases (colorectal, melanoma, kidney, and others). Patients also had different previous and additional treatments, including chemotherapy and radiotherapy, whose effects on the outcomes could not be separated out. With only 5 patients who had NSCLC (primary non-small cell lung cancer), the study simply could not perform a meaningful statistical analysis of whether cancer type affected outcomes — the authors list this as a specific limitation, referencing the work of Hiraki and Garetto, who studied histology (tissue type) as a potential factor. **Third, no tissue confirmation of cure.** Follow-up consisted only of CT imaging — looking at lesion size, shape, and contrast enhancement. The researchers did not take biopsy samples to histologically prove (confirm under a microscope) that all cancer cells were dead. Some studies use FDG-PET/CT scans (a type of imaging that shows metabolic activity — living cancer cells consume sugar and light up on PET scans) to assess treatment response, which can be more sensitive. This study did not. **Fourth, imaging inconsistencies.** CT scans were performed with patients positioned differently in the imaging plane for axial imaging, which can introduce small measurement variations. **Fifth, missing quality-of-life data.** Given that overall survival was a key endpoint, the authors note that quality-of-life assessment would have rounded out the picture of what patients actually experienced. For a treatment meant to be gentler than surgery, knowing whether patients felt better matters. **Finally, the authors note** that median follow-up was 14 months, with a maximum of 81 months. Some tumors can recur later than 14 months after treatment, so the 85.3% local control rate could potentially decrease with longer follow-up in some patients. Despite these limitations, the study's results align with multiple other clinical trials in recent years, and its detailed analysis of predictive factors is a genuine contribution to the field. ## What This Means for Patients: Clinical Implications So, what should a patient facing lung tumors take away from this research? **First, RFA is a proven, effective option when surgery, radiation, and chemotherapy are not available.** The 85.3% local tumor control rate, the 27-month median overall survival, and the low rate of serious complications all confirm that RFA works and is safe. For patients who cannot tolerate surgery, this is not a second-rate fallback — it is a real treatment with results in the same range as surgery for metastatic disease. **Second, smaller tumors clearly do better.** The single most important message for patients is that **tumor size matters most**. If you have a lung tumor smaller than 2 cm — especially smaller than 1 cm — RFA offers an excellent chance of control. With tumors larger than 2 cm, the recurrence rate climbs to about 29%, and patients should discuss with their doctors whether a different approach or a combination of treatments might be better. **Third, anatomical location is less important than previously thought.** Patients with tumors near blood vessels, airways, or the lung lining can be reassured: this study found no evidence that these locations reduce treatment success. Doctors do not need to steer clear of treating tumors in those spots. **Fourth, the side-effect profile is manageable.** A collapsed lung (pneumothorax) happens in about 1 in 7 procedures, but most resolve on their own or need only simple drainage. Serious complications leading to chest tubes or other interventions occur in fewer than 1 in 25 procedures. Death from the procedure itself is essentially nonexistent in experienced centers. The most common experience is: sedation, a needle insertion through the back or chest, 17 minutes of treatment, overnight observation, and a short recovery compared to surgery. **Fifth, for colorectal cancer patients specifically:** The median survival of 13 months and median time-to-recurrence of 8 months in this study reflect a mix of patients with varying disease burden. Patients with fewer, smaller metastases and better overall health tend to do considerably better, as the de Baere series with 62-month median survival shows. **Finally, treatment is becoming more personalized.** The study's authors note that finding tumor size to be the decisive factor underlines "the necessity of further technical development of RF technology in the future." They also predict that, for small tumors that have spread to the lung (oligometastatic disease), low-invasive techniques like RFA will increasingly replace surgery in selected patients. Future care will combine surgical, systemic (chemotherapy or immunotherapy), and interventional options tailored to the individual. The title of this field — interventional oncology — captures the shift: radiologists are no longer just diagnosing; they are treating, with outcomes that deserve serious consideration. If you or a loved one are considering RFA, the practical checklist to discuss with your care team includes: - What is the exact size of the tumor? (Under 2 cm is ideal) - How many tumors are present? (This study allowed up to 3 per lung) - What is your general performance status? (ECOG 0-2 was required here) - What is your platelet count? (Must be above 100 × 10⁹/L for safe clotting) - Who will perform the procedure, and how many RFA procedures do they do per year? (Experience reduces complication rates) - What follow-up schedule will you have? (In this study: CT at 1 month, then every 3 months) ## Frequently Asked Questions ### What is radiofrequency ablation (RFA) for lung tumors? RFA is a minimally invasive treatment that uses heat from radio waves to destroy tumors. A needle is placed through the skin into the tumor using CT scan guidance. The procedure takes about 17 minutes on average. It is an option when surgery, radiation, or chemotherapy are not suitable. ### What are the main risks and side effects of radiofrequency ablation? The most common side effect was a collapsed lung, called pneumothorax, which occurred in about 1 in 7 treatment sessions. Most were minor and self-limiting. Serious complications requiring chest tubes or other intervention occurred in fewer than 1 in 25 procedures. No deaths from the procedure were reported. ### What happens during and after a radiofrequency ablation procedure? Patients receive sedation and painkillers plus local anesthesia. A needle is inserted through the skin into the tumor using CT guidance. After ablation, patients are monitored and have chest X-rays at 4 and 24 hours. The median procedure time was 17 minutes. Recovery is typically shorter than after surgery. ### If my lung tumor can’t be removed with surgery, should I get a second opinion before choosing radiofrequency ablation (RFA)? For a patient with a lung tumor that can’t be treated with surgery, radiation, or chemotherapy, seeking a second opinion before committing to RFA helps confirm that RFA is appropriate and that tumor size is favorable. Local tumor control was 85.3% overall, but smaller tumors clearly do better: tumors under 1 cm had only 7.3% local progression, while 2–3 cm tumors progressed in 28.6% of cases. A second opinion can also compare RFA with alternatives such as microwave ablation or stereotactic radiotherapy. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information **Original article title:** Percutaneous radiofrequency ablation in the treatment of pulmonary malignancies- efficacy, safety and predictive factors **Authors:** Tina Streitparth, Denis Schumacher, Robert Damm, Bjoern Friebe, Konrad Mohnike, Ortrud Kosiek, Maciej Pech, Jens Ricke, and Florian Streitparth **Journal:** Oncotarget, 2018, Vol. 9 (No. 14), pp. 11722-11733 **Institutions:** Department of Radiology, University Hospital Munich, Munich, Germany; Department of Neurology, Clinic of Magdeburg; Department of Radiology, Otto-von-Guericke University Clinic Magdeburg; DTZ, Berlin, Germany **Publication date:** January 18, 2018 (received May 5, 2017; accepted November 11, 2017) **Keywords:** lung malignancies; radiofrequency ablation; colorectal cancer; microwave ablation **Funding/access note:** This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium with attribution to the original authors. This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Patients should discuss their individual treatment options with their oncology and interventional radiology care teams. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/using-radiofrequency-ablation-heat-to-treat-lung-tumors-what-patients-should-know-about-success-rates-safety-and-what-predicts-a-good-outcome